Drug Interactions between tipranavir and viloxazine
This report displays the potential drug interactions for the following 2 drugs:
- tipranavir
- viloxazine
Interactions between your drugs
tipranavir viloxazine
Applies to: tipranavir and viloxazine
MONITOR: Coadministration with viloxazine may increase the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or CYP450 2D6 leading to increased toxicity. The proposed mechanism is decreased clearance due to viloxazine-mediated inhibition of CYP450 3A4 and/or CYP450 2D6. The product labeling describes viloxazine as a weak inhibitor of CYP450 3A4 and CYP450 2D6.
MANAGEMENT: Caution is advised if viloxazine is used concomitantly with drugs that are substrates of CYP450 3A4 and/or CYP450 2D6, particularly those with a narrow therapeutic range. Monitor for adverse reactions of the CYP450 3A4 or CYP450 2D6 substrate and adjust dosages as needed.
References (1)
- (2021) "Product Information. Qelbree (viloxazine)." Supernus Pharmaceuticals Inc
Drug and food interactions
tipranavir food
Applies to: tipranavir
ADJUST DOSING INTERVAL: Food does not appear to substantially alter the pharmacokinetics of tipranavir. When tipranavir capsules or oral solution was coadministered with ritonavir capsules at steady-state, no clinically significant changes in tipranavir peak plasma concentration (Cmax) and systemic exposure (AUC) were observed under fed conditions (500 to 682 kcal, 23% to 25% calories from fat) relative to fasted conditions. The effect of food on tipranavir exposure during coadministration with ritonavir tablets has not been evaluated. High-fat foods may enhance the gastrointestinal absorption of tipranavir. In a multiple-dose study, administration of tipranavir capsules with a high-fat meal (868 kcal, 53% from fat, 31% from carbohydrates) increased the oral bioavailability of tipranavir by 31% compared to administration with toast and skimmed milk, but did not significantly affect tipranavir Cmax. Thus, tipranavir may be safely taken with standard or high-fat meals.
MANAGEMENT: Tipranavir coadministered with low-dose ritonavir should be taken with food to improve the gastrointestinal tolerability of ritonavir. According to the product labeling, tipranavir coadministered with ritonavir capsules or solution can be taken with or without meals, whereas tipranavir coadministered with ritonavir tablets must be taken with meals.
References (4)
- (2005) "Product Information. Aptivus (tipranavir)." Boehringer-Ingelheim
- Cerner Multum, Inc. "UK Summary of Product Characteristics."
- Canadian Pharmacists Association (2006) e-CPS. http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink
- Cerner Multum, Inc. "Australian Product Information."
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.